TTrialPathMatch Me to Trials
← Back to trials
RecruitingHR+ Breast CancerTriple Negative Breast Cancer (TNBC)CCNE1 Amplified Advanced Solid Tumors

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Eligible age

18+ yrs

Accepts

All genders

Locations

16 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tumors with CCNE1 amplification). Main questions to answer include: * What is the recommended dose for expansion and/or Phase 2, for both monotherapy and in combination with ET * What medical issues/symptoms do participants experience when taking NKT5097 as monotherapy as well as in combination with ET

Sponsor: NiKang Therapeutics, Inc.

You may qualify if…

  • ✓ Able to provide written informed consent
  • ✓ Advanced unresectable or metastatic solid tumor (Part 1, 2 \& 3 only)
  • ✓ Advanced unresectable or metastatic HR+/HER2- breast cancer (Part 4 \& 5 only)
  • ✓ Refractory to or unable to tolerate existing therapies (Part 1, 2 \& 4 only)
  • ✓ Measurable or evaluable disease (Part 1, 2, \& 4 only).
  • ✓ Measurable disease (Part 3 \& 5 only)
  • ✓ Eighteen years of age or older
  • ✓ ECOG status of 0 or 1

You may not qualify if…

  • ✕ Advanced solid tumor that is a candidate for curative treatment
  • ✕ History of another malignancy except for the following: adequately treated local basal cell or squamous carcinoma of the skin, in situ cervical cancer, adequately treated papillary noninvasive bladder cancer, other adequately treated Stage I or Stage II cancers currently in complete remission
  • ✕ Not recovered from the effects of prior anticancer therapy
  • ✕ Clinically significant cardiovascular event, including myocardial infarction, arterial thromboembolism, or cerebrovascular thromboembolism, within 6 months
  • ✕ Known active CNS metastases and/or carcinomatous meningitis
  • ✕ Active interstitial lung disease requiring treatment
  • ✕ History of uveitis, retinopathy, or other clinically significant retinal disease
  • ✕ Major surgery within 30 days of administration of first dose

Where it's recruiting

California

Duarte · La Jolla

Colorado

Denver

Connecticut

New Haven

District of Columbia

Washington D.C.

Florida

Sarasota

Iowa

Iowa City

Michigan

Grand Rapids

Missouri

St Louis

Nevada

Las Vegas

Ohio

Cleveland

Pennsylvania

Pittsburgh

Source: ClinicalTrials.gov · NCT07029399 · last updated 2026-11-05

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors · TrialPath